Skip to main content
Medicamen Biotech Ltd. logo

Medicamen Biotech Ltd. — Investor Relations & Filings

Ticker · MEDICAMEQ ISIN · INE646B01010 LEI · 894500T0ULD27B7W4Y03 BSE.NS Manufacturing
Open in API
Filings indexed 277 across all filing types
Latest filing 2024-04-17 Regulatory Filings
Country IN India
Listing BSE.NS MEDICAMEQ

About Medicamen Biotech Ltd.

https://www.medicamen.com/

Medicamen Biotech Ltd. specializes in the research, development, and manufacturing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities compliant with international quality standards, including WHO-GMP. Its product portfolio encompasses various therapeutic segments such as oncology, cardiology, central nervous system, and anti-infectives, delivered through dosage forms like tablets, capsules, and liquid orals. A significant strategic focus is placed on its specialized oncology division, which develops complex generic formulations. The company serves global markets, leveraging its research and development capabilities to provide high-quality healthcare solutions. Its operations are supported by dedicated R&D centers focused on formulation development and process chemistry.

Recent filings

Filing Released Lang Actions
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming details about securities dematerialized/rematerialized for the quarter and year ended March 31, 2024. It is addressed to stock exchanges and signed by the company secretary. The document is short (1639 characters) and primarily a certification letter rather than a financial report or announcement of voting results, capital changes, or management changes. It does not contain financial statements or detailed report data. Therefore, it fits best under Regulatory Filings (RNS) as an official compliance certificate.
2024-04-17 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a notification titled 'Intimation of Closure of Trading Window' addressed to stock exchanges. It informs about the closure period of the trading window for directors and designated persons around the time of the announcement of audited financial results for the quarter and year ended March 31, 2024. The document does not contain any financial data, results, or detailed report but is a regulatory announcement related to insider trading restrictions prior to financial results disclosure. It is short (1681 characters) and serves as a regulatory filing to inform the exchange and public about trading restrictions. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than a financial report or other specific filing type.
2024-04-01 English
Trading Plan under PIT
Director's Dealing Classification · 100% confidence The document is a notification addressed to stock exchanges regarding a disclosure under SEBI regulations about insider trading. It specifically mentions the sale of shares by an immediate relative of the CEO, which is a personal share transaction by a company director or related party. The document references Regulation 7(3) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, which governs insider trading disclosures. This fits the definition of a Director's Dealing report, which involves reporting personal share transactions by company directors and executives. The document is short and focused solely on this disclosure, with no financial statements or other report content.
2024-03-26 English
Updates
Regulatory Filings Classification · 95% confidence The document is an announcement addressed to stock exchanges (BSE and NSE) under Regulation 30 of SEBI (LODR) Regulations, 2015. It informs about an audit conducted by the Ethiopian FDA on the company's Oncology Plant and the submission of dossiers for oncology products. There is no financial data, no detailed report, no voting results, no management changes, or other specific report content. The document is short (995 characters) and serves as a regulatory update or compliance announcement. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-03-26 English
Updates
Regulatory Filings Classification · 95% confidence The document text is extremely short (652 characters) and consists solely of digital signature information without any substantive content related to financial performance, management changes, or other reportable events. There is no mention of any report, announcement, or financial data. Given the lack of content and the presence of only signatures, this document does not fit into any specific report category and is best classified as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings.
2024-03-20 English
Trading Plan under PIT
Director's Dealing Classification · 100% confidence The document is a short disclosure letter addressed to stock exchanges regarding a share transaction by an immediate relative of the CEO, specifically the sale of equity shares. It references compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and is a notification of insider trading activity. The document length is only 1205 characters, indicating it is a brief regulatory announcement rather than a detailed report. This fits the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades).
2024-03-16 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.